ABIMONO 1 OV VAG 600MG

ABIMONO

active ingredients

ABIMONO 600 mg vaginal eggs An ovum contains Active Ingredient: Isoconazole nitrate 600 mg ABIMONO 1% vaginal cream 100 g cream contain: Active ingredient: Isoconazole nitrate 1 g For full list of excipients, see paragraph 6.1.

Excellent

Ovuli: Boric acid, semisynthetic glycerides. Vaginal cream: Sorbitanmonostearato, Poliossietilen sorbitanmonostearato, Cetilstearilic alcohol, White viseline, Isopropil miristato, Distilled water.

Therapeutic indications

Mycotic vulvovaginal infections also with bacterial superinfection.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. Hypersensitivity ascertained or presumed to other antifungal imidazolics derivatives.

Population

Vaginal egg: 1 egg to be introduced deeply into the vagina.. The possibility of a treatment greater than one day must be evaluated by the attending physician. Vaginal cream: an application per day and for a week, except for a different prescription. The applicator filled with cream, must be introduced deeply into the vagina, emptied in cavity and then thrown after use. Treatment should not be carried out during menstruation. A contemporary use of ABIMONO dermatological cream by the partner. Use of disposable applicator: • Remove the pipe cap and screw the applicator on the pipe. • Push the plunger gradually to the stop position. • Fill the applicator with a slight pressure on the tube. • Remove the applicator from the tube and reposition the cap. • Introduce the filled applicator, deeply into the vagina and empty it into cavity, pushing the plunger.

Conservation

Ovuli: Do not store at temperature above 30°C Vaginal cream: This medicine does not require any particular condition of conservation.

Warnings

Avoid contact with eyes; it is recommended to thoroughly wash your hands after use of the medicine. During treatment and on the days immediately following it is necessary, to avoid a reinfection, change daily and sterilize by boiling, towels and underwear. The use, especially if prolonged, of topical products may give rise to awareness-raising phenomena (see paragraph 4.8). In this case it is necessary to stop the treatment and establish adequate therapy. The contemporary use of latex condoms or diaphragms with vaginal antimicrobial preparations can decrease the effectiveness of latex contraceptives. Therefore, products as ABIMONO should not be used together with diaphragms or latex condoms. Patients using spermicides should consult their physician as each local vaginal treatment can make spermicide inactive Vaginal cream contains as excipient cetosterial alcohol that can cause local skin reactions (add es.dermatiti from contact).

Interactions

Crusade sensitivity reactions between isoconazole, miconazole, econazole and tioconazole are possible. Concurrent treatments with nitrate isoconazole administered intra-vaginal and cumarin-type anticoagulants (for example: warfarin) can increase the plasma levels of the anti-agulant.

Effects

The adverse reactions observed with this type of medicines were reported burning, irritation and vaginal pain, pelvic cramps, rashes, headaches, dizziness. In these cases it is necessary to suspend treatment and establish suitable therapy. It will also be involved in nonsensical microorganisms. Reporting of suspicious adverse reactions The indication of suspicious adverse reactions that occur after the authorization of the medicinal product is important. as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa

Overdosing

No known overdose cases.

Pregnancy In case of pregnancy, patients must be informed that the applicator for the administration of ABIMONO must be used with caution (see also paragraph 4.2). In pregnant women, the product should be administered in cases of actual need, under the direct control of the doctor. Breeding It is not known whether isoconazole or nitrate isoconazole is excreted in breast milk. The risk for infants cannot be excluded. Fertility Preclinical data does not indicate risks to fertility.

Source: Farmadati